Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000
Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000
复制标题
DOI：
10.7326/0003-4819-142-11-200506070-00006
复制
发表时间：
2005-06-07
影响因子：
39.2
通讯作者：
Seger, AC
中科院分区：
文献类型：
--
作者：
Haas, JS;Phillips, KA;Seger, AC
背景：仿制药替代是减少处方药支出的一种机制。有限的信息是可用的潜在储蓄与仿制药的替代。目的：估计潜在储蓄与广泛替代的仿制药。设计：横截面，全国代表性调查的非制度化的成年人。设置：美国。参与者：成人包括在医疗支出小组调查家庭组成部分，1997- 2000年。测量：使用多药（即，一种药物可在一个品牌和>= 1通用配方）或通用的药物和潜在的成本节约与广泛的通用替代所有多药products.Results：五十六%的门诊药物是多药产品，占门诊药物总支出的41%。在这些多种药物中，61%作为仿制药分发。如果在2000年用一种非专利药替代所有相应的名牌门诊药物，每人每年节省的药物支出中位数将为45.89美元（四分位数范围，10.35美元至158.06美元）对于65岁以下的成年人和78.05美元（四分位数范围，19.94美元至241.72美元）至少65岁的成年人。在这些年龄组中，国民储蓄将达到59亿美元，（95% CI，55亿至62亿美元）和29亿美元（Cl，26亿美元至31亿美元），约占药品支出的11%。没有关于个人处方集的具体信息，因此，作者无法估计有多少潜在的节省将有利于个人或他或她的健康计划。结论：虽然广泛替代非专利药品只会影响药品支出的一小部分，但它可以带来大量绝对节省。
Background: Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution.Objective: To estimate the potential savings associated with broad substitution of generic drugs.Design: Cross-sectional, nationally representative survey of noninstitutionalized adults.Setting: United States.Participants: Adults included in the Medical Expenditure Panel Survey Household Component, 1997-2000.Measurements: Use of a multisource drug (that is, a drug available in a brand-name and >= 1 generic formulation) or a generic drug and the potential cost savings associated with broad generic substitution for all multisource products.Results: Fifty-six percent of all outpatient drugs were multisource products, accounting for 41% of total outpatient drug expenditures. Of these multisource drugs, 61% were dispensed as a generic. If a generic had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual savings in drug expenditures per person would have been $45.89 (interquartile range, $10.35 to 158.06) for adults younger than 65 years of age and $78.05 (interquartile range, $19.94 to $241.72) for adults at least 65 years of age. in these age groups, the national savings would have been $5.9 billion (95% Cl, $5.5 billion to $6.2 billion) and $2.9 billion (Cl, $2.6 billion to $3.1 billion), respectively, representing approximately 11% of drug expenditures.Limitations: Specific information about an individual's formulary was not available, so the authors could not estimate how much of the potential savings would benefit an individual or his or her health plan.Conclusion: Although broad substitution of generic drugs would affect only a modest percentage of drug expenditures, it could result in substantial absolute savings.